← Back to the studies fieldPERMANENT CTIS TRIAL DOSSIER

2023-505575-69-01

Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

Public registry stateAuthorised

CLAIM BOUNDARY

This dossier documents a medicinal trial—not proof of efficacy.

Registration, authorisation of a trial application, trial start, result disclosure and marketing authorisation are different facts. The dossier claims neither clinical efficacy nor safety, deployment or causality.

CTIS record ≠ efficacy ≠ marketing authorisation

REGISTRY FACTS

What CTIS publishes about this trial

EUCT number: 2023-505575-69-01
Trial status: Authorised
Sponsor: not published
Trial region: EEA
Phase: 5
Trial category: 2
Low-intervention trial: no
Estimated EU start: 06 July 2026
Decision date: 08 July 2026
Published: 14 July 2026
Estimated end: 06 July 2034

EXACT AI EVIDENCE

The original text determines inclusion.

Terms count only in allowlisted public CTIS fields. Sponsor, medical condition, phase or a generic software reference alone is not AI evidence.

“For FOSTER evolving study platform : To improve the characterization of lung nodules using artificial intelligence.”

Source field: authorizedApplication.authorizedPartI.trialDetails.trialInformation.trialObjective.secondaryObjectives[11].secondaryObjective
Matched term: artificial intelligence

MEDICAL CONTEXT

Conditions and therapeutic areas

Reported medical conditions

Osteosarcoma

Therapeutic areas

Diseases [C] - Neoplasms [C04]4

COUNTRY TRACKS

Every country retains its own published state.

A status in one country is not transferred to another. Decision dates and status histories remain separate source facts.

Denmark

Authorised

First decision: 08 July 2026
Latest decision: 08 July 2026

08 July 2026Authorised
08 July 2026Authorised

Finland

Authorised

First decision: 08 July 2026
Latest decision: 08 July 2026

08 July 2026Authorised
08 July 2026Authorised

France

Authorised

First decision: 10 July 2026
Latest decision: 10 July 2026

10 July 2026Authorised
10 July 2026Authorised

Italy

Authorised

First decision: 08 July 2026
Latest decision: 08 July 2026

08 July 2026Authorised
08 July 2026Authorised

Netherlands

Authorised

First decision: 10 July 2026
Latest decision: 10 July 2026

10 July 2026Authorised
10 July 2026Authorised

Poland

Authorised

First decision: 13 July 2026
Latest decision: 13 July 2026

13 July 2026Authorised
13 July 2026Authorised

Spain

Authorised

First decision: 10 July 2026
Latest decision: 10 July 2026

10 July 2026Authorised
10 July 2026Authorised

Sweden

Authorised

First decision: 08 July 2026
Latest decision: 08 July 2026

08 July 2026Authorised
08 July 2026Authorised

TRIAL APPLICATIONS

Submission, decision and country state remain separate

IN-1

INITIAL

Authorised

Trial status: Authorised
Submitted: 18 March 2026
Decided: 08 July 2026

Decisions08 July 2026 · Authorized Conditions08 July 2026 · Authorized Conditions08 July 2026 · Authorized Conditions08 July 2026 · Authorized Conditions10 July 2026 · Authorized Conditions10 July 2026 · Authorized Conditions10 July 2026 · Authorized Conditions13 July 2026 · Authorized Conditions

Country statusDenmark · AuthorisedFinland · AuthorisedFrance · AuthorisedItaly · AuthorisedNetherlands · AuthorisedPoland · AuthorisedSpain · AuthorisedSweden · Authorised

SOURCE-DATED CHRONICLE

Official dates, not an efficacy narrative.

The chronicle sorts published CTIS events. i6eal observation times follow on a separate clock.

18 March 2026Application Submitted
Application IN-1 · Authorised
18 June 2026Country Assessment
Sweden · Application IN-1 · Authorized Conditions
30 June 2026Country Assessment
France · Application IN-1 · Authorized Conditions
01 July 2026Country Assessment
Spain · Application IN-1 · Authorized Conditions
03 July 2026Country Assessment
Netherlands · Application IN-1 · Authorized Conditions
03 July 2026Country Assessment
Denmark · Application IN-1 · Authorized Conditions
06 July 2026Country Assessment
Poland · Application IN-1 · Authorized Conditions
06 July 2026Country Assessment
Italy · Application IN-1 · Authorized Conditions
06 July 2026Country Assessment
Finland · Application IN-1 · Authorized Conditions
08 July 2026Application Status
Application IN-1 · Authorised
08 July 2026Country Decision
Italy · Application IN-1 · Authorized Conditions
08 July 2026Country Decision
Sweden · Application IN-1 · Authorized Conditions
08 July 2026Country Decision
Finland · Application IN-1 · Authorized Conditions
08 July 2026Country Decision
Denmark · Application IN-1 · Authorized Conditions
10 July 2026Country Decision
Spain · Application IN-1 · Authorized Conditions
10 July 2026Country Decision
Netherlands · Application IN-1 · Authorized Conditions
10 July 2026Country Decision
France · Application IN-1 · Authorized Conditions
13 July 2026Country Decision
Poland · Application IN-1 · Authorized Conditions
23 July 2026Trial Status Observed
Authorised

Observed by i6eal

First observed: 23 Jul 2026, 13:19
Last observed: 23 Jul 2026, 15:03
Materially modified: 23 July 2026

RESULT DISCLOSURE

Disclosure is a separate registry fact.

No result disclosure is published in this projection. This means neither that results do not exist nor that a deadline has been missed.

PROVENANCE

From the dossier back to the official record

The public CTIS record remains authoritative. The i6eal files are a deterministic, bounded projection.

Open public CTIS record ↗Open CTIS retrieval source ↗Machine-readable dossier · JSON ↓Structured metadata · JSON-LD ↓

i6eal (2026): EU AI Studies Monitor, CTIS trial 2023-505575-69-01, data state 23 July 2026. https://i6eal.de/en/tools/ki-studienmonitor/studie/2023-505575-69-01/

Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

This dossier documents a medicinal trial—not proof of efficacy.

What CTIS publishes about this trial

The original text determines inclusion.

Conditions and therapeutic areas

Reported medical conditions

Therapeutic areas

Every country retains its own published state.

Submission, decision and country state remain separate

Official dates, not an efficacy narrative.

Application IN-1 · Authorised

Sweden · Application IN-1 · Authorized Conditions

France · Application IN-1 · Authorized Conditions

Spain · Application IN-1 · Authorized Conditions

Netherlands · Application IN-1 · Authorized Conditions

Denmark · Application IN-1 · Authorized Conditions

Poland · Application IN-1 · Authorized Conditions

Italy · Application IN-1 · Authorized Conditions

Finland · Application IN-1 · Authorized Conditions

Application IN-1 · Authorised

Italy · Application IN-1 · Authorized Conditions

Sweden · Application IN-1 · Authorized Conditions

Finland · Application IN-1 · Authorized Conditions

Denmark · Application IN-1 · Authorized Conditions

Spain · Application IN-1 · Authorized Conditions

Netherlands · Application IN-1 · Authorized Conditions

France · Application IN-1 · Authorized Conditions

Poland · Application IN-1 · Authorized Conditions

Authorised

Disclosure is a separate registry fact.

From the dossier back to the official record

Useful next steps